A Phase Ib/II Study of AK104#PD-1 / CTLA-4 Bispecific Antibody# and AK117#Anti-CD47 Antibody# in Combination With or Without Chemotherapy in Advanced Malignant Tumors

NCT05235542 Phase 1/Phase 2 UNKNOWN

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) and AK117#AntiCD47 Antibody# combined with or without chemotherapy in advanced malignant tumors

Details

Lead sponsor	Akeso
Phase	Phase 1/Phase 2
Status	UNKNOWN
Enrolment	130
Start date	2022-07-12
Completion	2024-03

Conditions

• Advanced Malignant Tumors

Interventions

• AK104
• AK117
• Capecitabine tablets
• Oxaliplatin
• Cisplatin
• Paclitaxel
• Irinotecan
• Docetaxel
• 5-FU

Primary outcomes

• Number of patients with Adverse Events (AEs) — Up to approximately 2 years
• Objective Response Rate (ORR) — Up to approximately 2 years

Countries

China